Hematologic Oncology | Specialty

FDA Halts Enrollment on Tazemetostat Trials

April 24th 2018

The FDA has halted enrollment on clinical trials of tazemetostat in patients with various solid tumors and hematologic malignancies.

Expert Highlights Advances Across Lymphoma Subtypes

April 23rd 2018

Alison J. Moskowitz, MD, discusses the latest treatment advances across subtypes of lymphoma.

Expert Highlights Evolving Role of BMT in Hematologic Malignancies

April 20th 2018

Koen van Besien, MD, PhD, shares his insights on challenges with bone marrow transplant and on the potential future for these technologies in a time when the landscape is undergoing many changes.

Dr. Nathwani on the Standard of Care in Patients With Newly Diagnosed Multiple Myeloma

April 20th 2018

Nitya Nathwani, MD, assistant clinical professor, Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the standard of care in patients with newly diagnosed multiple myeloma.

FDA Approves Fostamatinib for Chronic ITP

April 18th 2018

The FDA has approved the SYK inhibitor fostamatinib as a second-line treatment for patients with chronic immune thrombocytopenia following insufficient response to a previous therapy.

Dr. Mesa Discusses the Management of Patients With MPNs

April 14th 2018

Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the management of patients with myeloproliferative neoplasms.

ASCT Remains Significant Upfront Option in AL Amyloidosis

April 12th 2018

Investigators found that autologous stem-cell transplantation improved overall survival and reduced treatment-related mortality in patients with immunoglobulin light chain amyloidosis.

Dr. Mesa Discusses Emerging Treatments for MPNs

April 5th 2018

Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses emerging treatment for myeloproliferative neoplasms (MPNs).

FDA Grants Moxetumomab Pasudotox Priority Review for Hairy Cell Leukemia

April 4th 2018

The FDA has granted a priority review to moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.

MRD Prognostic of Poorer Outcomes in AML

April 2nd 2018

Molecular minimal residual disease was associated with a higher rate of relapse and a lower rate of relapse-free survival and overall survival for patients with newly-diagnosed acute myeloid leukemia.

Dr. Mauro Discusses Updates in CML

April 2nd 2018

Michael J. Mauro, MD, a hematologist and leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center, discusses updates in chronic myeloid leukemia.

Novel Radiolabeled ADC Could Improve Outcomes in High-Risk AML

April 2nd 2018

Older patients with active, relapsed, or refractory acute myeloid leukemia have a low survival rate, very poor risk assessments, and limited therapeutic options, with conventional care consisting primarily of salvage chemotherapy.

Nivolumab Delivers Durable Response in Hodgkin Lymphoma at 18 Months

April 2nd 2018

In an extended follow-up of results from the CheckMate-205 trial, nivolumab (Opdivo) induced an overall objective response rate of 69% in patients with relapsed/refractory classical Hodgkin lymphoma after autologous hematopoietic cell transplantation.

Dr. Goldberg on FDA-Approved Agents for Patients With AML

April 2nd 2018

Stuart L. Goldberg, MD, hematologist, John Theurer Cancer Center, discusses the use of 4 FDA-approved agents for patients with acute myeloid leukemia (AML) with varying genetic alterations.

AML Treatment Additions Encouraging, But MDS Landscape Still Facing Challenges

March 31st 2018

Stuart L. Goldberg, MD, discusses the management of patients with acute myeloid leukemia as well as those with myelodysplastic syndrome.

The Evolving Treatment Landscape of CLL

March 31st 2018

Relapsed/Refractory CLL: Evaluating Other Novel Agents

March 31st 2018

Novel Approaches to Treating Relapsed/Refractory CLL

March 31st 2018

Continuing Therapy in Relapsed/Refractory CLL

March 31st 2018

Evaluating Pharmacologic Agents in Relapsed/Refractory CLL

March 31st 2018